Impact of early use of long-acting injectable antipsychotics on functional outcome in first episode psychosis: a 3-year longitudinal study

References

• Abdel-Baki, A., Medrano, S., Maranda, C., Ladouceur, M., Tahir, R., Stip, E., & Potvin, S. (2020). Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis. International Clinical Psychopharmacology, 35(4), 221–228. https://doi.org/10.1097/yic.0000000000000310
   PubMed Web of Science ®Google Scholar
• Abdel-Baki, A., Thibault, D., Medrano, S., Stip, E., Ladouceur, M., Tahir, R., & Potvin, S. (2019). Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder. Early Intervention in Psychiatry, 14(1), 69–79. https://doi.org/10.1111/eip.12826
   PubMed Web of Science ®Google Scholar
• Addington, D., Addington, J., & Maticka-Tyndale, E. (1994). Specificity of the Calgary Depression Scale for schizophrenics. Schizophrenia Research, 11(3), 239–244. https://doi.org/10.1016/0920-9964(94)90017-5
   PubMed Web of Science ®Google Scholar
• Alvarez-Jimenez, M. (2012). Road to full recovery: Longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years. Psychological Medicine, 42, 595–606. https://doi.org/10.1017/S0033291711001504
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association, American Psychiatric Association, & Task Force on DSM-IV (2000). Diagnostic and statistical manual of mental disorders: DSM-IV-TR (4th ed.). American Psychiatric Association.
   Google Scholar
• Bell Lynum, K. S., Turkoz, I., & Kim, E. (2019). Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia. Early Intervention in Psychiatry, 13(3), 667–672. https://doi.org/10.1111/eip.12685
   PubMed Web of Science ®Google Scholar
• Birchwood, M., Todd, P., & Jackson, C. (1998). Early intervention in psychosis. The critical period hypothesis. The British Journal of Psychiatry. Supplement, 172(33), 53–59. https://doi.org/10.1192/S0007125000297663
   PubMedGoogle Scholar
• Bossie, C. A., Turkoz, I., Alphs, L., Mahalchick, L., & Fu, D. J. (2017). Paliperidone palmitate once-monthly treatment in recent onset and chronic illness patients with schizoaffective disorder. The Journal of Nervous and Mental Disease, 205(4), 324–328. https://doi.org/10.1097/nmd.0000000000000646
   PubMed Web of Science ®Google Scholar
• Bradford, D. W., Perkins, D. O., & Lieberman, J. A. (2003). Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs, 63(21), 2265–2283. https://doi.org/10.2165/00003495-200363210-00001
   PubMed Web of Science ®Google Scholar
• Brugnoli, R., Rapinesi, C., Kotzalidis, G. D., Marcellusi, A., Mennini, F. S., De Filippis, S., Carrus, D., Ballerini, A., Francomano, A., Ducci, G., Del Casale, A., & Girardi, P. (2016). Model of Management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs). Rivista di Psichiatria, 51(2), 47–59. https://doi.org/10.1708/2246.24194
   PubMed Web of Science ®Google Scholar
• Correll, C. U., Citrome, L., Haddad, P. M., Lauriello, J., Olfson, M., Calloway, S. M., & Kane, J. M. (2016). The use of long-acting injectable antipsychotics in schizophrenia: Evaluating the evidence. The Journal of Clinical Psychiatry, 77(suppl 3), 1–24. https://doi.org/10.4088/JCP.15032su1
   PubMed Web of Science ®Google Scholar
• Devrimci-Ozguven, H., Atmaca, M., Baran, Z., Cengisiz, C., Çinar, C., Erol, A., Genç, Y., Karadağ, H., Karakülah, K., Karasu, U., Kaya, M. C., Kizil, E., Özcan, H., Tiryaki, A., Üçok, A., Varlik, C., Yazar, S. M., & Yildiz, M. (2019). Efficacy and safety of paliperidone palmitate treatment in patients with schizophrenia: A real-world multicenter, retrospective, mirror-image study. Journal of Clinical Psychopharmacology, 39(6), 604–610. https://doi.org/10.1097/JCP.0000000000001133
   PubMed Web of Science ®Google Scholar
• Drake, R., Mueser, K., & McHugo, G. (1996). Clinician rating scales: Alcohol Use Scale (AUS), Drug Use Scale (DUS), and Substance Abuse Treatment Scale (SATS). In: L. Sederer, B. Dickey (Eds.), Outcomes assessment in clinical practice (pp. 113–116). Williams e Wilkins.
   Google Scholar
• Dubois, V., Peuskens, J., Geerts, P., & Detraux, J. (2014). Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: Results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES). Early Intervention in Psychiatry, 8(1), 39–49. https://doi.org/10.1111/eip.12017
   PubMed Web of Science ®Google Scholar
• Emsley, R., Hargarter, L., Bergmans, P., Uglešić, B., Sengül, A. C., Petralia, A., Khannanova, A., Cherubin, P., & Schreiner, A. (2017). Once-monthly paliperidone palmitate in early stage schizophrenia—A retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia. Neuropsychiatric Disease and Treatment, 13, 2261–2269. https://doi.org/10.2147/NDT.S142634
   PubMed Web of Science ®Google Scholar
• Emsley, R., Oosthuizen, P., Koen, L., Niehaus, D. J., Medori, R., & Rabinowitz, J. (2008). Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: A study with risperidone long-acting injection. International Clinical Psychopharmacology, 23(6), 325–331. https://doi.org/10.1097/YIC.0b013e32830c2042
   PubMed Web of Science ®Google Scholar
• Frederick, T. J., Chwalek, M., Hughes, J., Karabanow, J., & Kidd, S. (2014). How stable is stable? Defining and measuring housing stability. Journal of Community Psychology, 42(8), 964–979. https://doi.org/10.1002/jcop.21665
   Web of Science ®Google Scholar
• Giordano, G. (2020). Aripiprazole long-acting injection during first episode schizophrenia–An exploratory analysis. Front Psychiatry, 10, 935–935. https://doi.org/10.3389/fpsyt.2019.00935
   PubMed Web of Science ®Google Scholar
• Godley, C. (1987). Vers une politique municipale pour les sans-abri. Rapport du comité des sans-abri déposé au conseil municipal de Montréal.
   Google Scholar
• Goldman, Y. (1992). Prophétie et royauté au retour de l'exil: Les origines littéraires de la forme massorétique du Livre de Jérémie. In Orbis biblicus et orientalis (Vol. 118). Universitätsverlag; Vandenhoeck & Ruprecht.
   Google Scholar
• Group, E. P. G. W. (2016). Australian clinical guidelines for early psychosis: A brief summary for practitioners. Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne (2nd ed.).
   Google Scholar
• Hall, R. C. W. (1995). Global assessment of functioning. Psychosomatics, 36(3), 267–275. https://doi.org/10.1016/S0033-3182(95)71666-8
   PubMed Web of Science ®Google Scholar
• Hargarter, L., Bergmans, P., Cherubin, P., Keim, S., Conca, A., Serrano-Blanco, A., Bitter, I., Bilanakis, N., & Schreiner, A. (2016). Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia. Expert Opinion on Pharmacotherapy, 17(8), 1043–1053. https://doi.org/10.1080/14656566.2016.1174692
   PubMed Web of Science ®Google Scholar
• Hargarter, L., Bergmans, P., Cherubin, P., & Schreiner, A. (2016). Clinical and functional response to paliperidone palmitate in early schizophrenia–A retrospective observational study in newly diagnosed patients treated over a 12-month period. European Psychiatry, 33(S1), S250–S251. https://doi.org/10.1016/j.eurpsy.2016.01.636
   Google Scholar
• Harrison, G., Hopper, K., Craig, T., Laska, E., Siegel, C., Wanderling, J., Dube, K. C., Ganev, K., Giel, R., An der Heiden, W., Holmberg, S. K., Janca, A., Lee, P. W., León, C. A., Malhotra, S., Marsella, A. J., Nakane, Y., Sartorius, N., Shen, Y., … Wiersma, D. (2001). Recovery from psychotic illness: A 15- and 25-year international follow-up study. The British Journal of Psychiatry: The Journal of Mental Science, 178, 506–517. https://doi.org/10.1192/bjp.178.6.506
   PubMed Web of Science ®Google Scholar
• Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T. Jr. (1984). The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin, 10(3), 388–398. https://doi.org/10.1093/schbul/10.3.388
   PubMed Web of Science ®Google Scholar
• Iyer, S. N., Mangala, R., Anitha, J., Thara, R., & Malla, A. K. (2011). An examination of patient-identified goals for treatment in a first-episode programme in Chennai, India. Early Intervention in Psychiatry, 5(4), 360–365. https://doi.org/10.1111/j.1751-7893.2011.00289.x
   PubMed Web of Science ®Google Scholar
• Juckel, G., & Morosini, P. L. (2008). The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. Current Opinion in Psychiatry, 21(6), 630–639. https://doi.org/10.1097/YCO.0b013e328314e144
   PubMed Web of Science ®Google Scholar
• Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P. M., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., Hummer, M., Dollfus, S., López-Ibor, J. J., Hranov, L. G., Gaebel, W., Peuskens, J., Lindefors, N., Riecher-Rössler, A., & Grobbee, D. E. (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet, 371(9618), 1085–1097. https://doi.org/10.1016/s0140-6736(08)60486-9
   PubMed Web of Science ®Google Scholar
• Kane, J. M., Kishimoto, T., & Correll, C. U. (2013). Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. Journal of Clinical Epidemiology, 66(8 Suppl), S37–S41. https://doi.org/10.1016/j.jclinepi.2013.01.012
   PubMed Web of Science ®Google Scholar
• Kane, J. M., Schooler, N. R., Marcy, P., Correll, C. U., Achtyes, E. D., Gibbons, R. D., & Robinson, D. G. (2020). Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia. JAMA Psychiatry, 77(12), 1217–1218. https://doi.org/10.1001/jamapsychiatry.2020.2076
   PubMed Web of Science ®Google Scholar
• Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276. https://doi.org/10.1093/schbul/13.2.261
   PubMed Web of Science ®Google Scholar
• Kim, B., Lee, S. H., Choi, T. K., Suh, S., Kim, Y. W., Lee, E., & Yook, K. H. (2008). Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 32(5), 1231–1235. https://doi.org/10.1016/j.pnpbp.2008.03.012
   PubMed Web of Science ®Google Scholar
• Kishimoto, T., Nitta, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2013). Long-acting injectable versus oral antipsychotics in schizophrenia: A systematic review and meta-analysis of mirror-image studies. The Journal of Clinical Psychiatry, 74(10), 957–965. https://doi.org/10.4088/JCP.13r08440
   PubMed Web of Science ®Google Scholar
• Lafeuille, M. H., Dean, J., Carter, V., Duh, M. S., Fastenau, J., Dirani, R., & Lefebvre, P. (2014). Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. Current Medical Research and Opinion, 30(8), 1643–1655. https://doi.org/10.1185/03007995.2014.915211
   PubMed Web of Science ®Google Scholar
• Llorca, P. M., Abbar, M., Courtet, P., Guillaume, S., Lancrenon, S., & Samalin, L. (2013). Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry, 13, 340. https://doi.org/10.1186/1471-244x-13-340
   PubMed Web of Science ®Google Scholar
• McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., & Strakowski, S. D. (2007). Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. American Journal of Psychiatry, 164(7), 1050–1060. https://doi.org/10.1176/ajp.2007.164.7.1050
   PubMed Web of Science ®Google Scholar
• Montemagni, C., Frieri, T., & Rocca, P. (2016). Second-generation long-acting injectable antipsychotics in schizophrenia: Patient functioning and quality of life. Neuropsychiatric Disease and Treatment, 12, 917–929.
   PubMed Web of Science ®Google Scholar
• Mustafa, S., Bougie, J., Miguelez, M., Clerzius, G., Rampakakis, E., Proulx, J., & Malla, A. (2019). Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: A Canadian naturalistic non-interventional prospective cohort study. BMC Psychiatry, 19(1), 114. https://doi.org/10.1186/s12888-019-2103-x
   PubMed Web of Science ®Google Scholar
• NICE (2014). Psychosis and schizophrenia in adults: prevention and management; national clinical practice guidelines number. National Institute for Clinical Excellence. Retrieved October 12, 2017, from https://www.nice.org.uk/guidance/cg178/chapter/
   Google Scholar
• Napryeyenko, O., Burba, B., Martinez, G., Neznanov, N. G., Fischel, T., Baylé, F. J., Corrivetti, G., Smeraldi, E., Rabinowitz, J., & Schreiner, A. (2010). Risperidone long-acting injectable in recent-onset schizophrenia examined with clinician and patient self-report measures. Journal of Clinical Psychopharmacology, 30(2), 200–202. https://doi.org/10.1097/JCP.0b013e3181d438e2
   PubMed Web of Science ®Google Scholar
• Nicole, L., Abdel-Baki, A., Lesage, A., Granger, B., Stip, E., & Lalonde, P. (2007). [Study of the follow-up of early psychosis at the Université de Montréal (L'Etude de Suivi des Psychoses Emergentes de l'Université de Montréal (ESPEUM)): Context, objectives and methodology]. Sante Mentale au Quebec, 32(1), 317–331. https://doi.org/10.7202/016523ar
   PubMedGoogle Scholar
• Padhi, A., & Fineberg, N. (2010). Clinical Global Impression Scales. In I. P. Stolerman (Ed.), Encyclopedia of psychopharmacology (p. 303). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-540-68706-1_1422
   Google Scholar
• Parellada, E., Andrezina, R., Milanova, V., Glue, P., Masiak, M., Turner, M. S. J., Medori, R., & Gaebel, W. (2005). Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. Journal of Psychopharmacology, 19(5_suppl), 5–14. https://doi.org/10.1177/0269881105056513
   PubMed Web of Science ®Google Scholar
• Peters, L., Krogmann, A., von Hardenberg, L., Bodeker, K., Nohles, V. B., & Correll, C. U. (2019). Long-acting injections in schizophrenia: A 3-year update on randomized controlled trials published January 2016–March 2019. Current Psychiatry Reports, 21(12), 124. https://doi.org/10.1007/s11920-019-1114-0
   PubMed Web of Science ®Google Scholar
• Peters-Strickland, T., Baker, R. A., Such, P., Zhang, P., & Madera, J. J. (2019). The effect of aripiprazole once-monthly on personal and social functioning: Post hoc analyses of acute and long-term studies. Neuropsychiatric Diseases and Treatment, 15, 1659–1669. https://doi.org/10.2147/NDT.S198241
   PubMed Web of Science ®Google Scholar
• Phahladira, L., Luckhoff, H. K., Asmal, L., Kilian, S., Scheffler, F., Plessis, S. d., Chiliza, B., & Emsley, R. (2020). Early recovery in the first 24 months of treatment in first-episode schizophrenia-spectrum disorders. NPJ Schizophrenia, 6(1), 2. https://doi.org/10.1038/s41537-019-0091-y
   PubMed Web of Science ®Google Scholar
• Rabinovitch, M., Bechard-Evans, L., Schmitz, N., Joober, R., & Malla, A. (2009). Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis. The Canadian Journal of Psychiatry, 54(1), 28–35. https://doi.org/10.1177/070674370905400106
   PubMed Web of Science ®Google Scholar
• Rabinowitz, J., Napryeyenko, O., Burba, B., Martinez, G., Neznanov, N. G., Fischel, T., Baylé, F. J., Cavallaro, R., Smeraldi, E., & Schreiner, A. (2011). Premorbid functioning and treatment response in recent-onset schizophrenia: Prospective study with risperidone long-acting injectable. Journal of Clinical Psychopharmacology, 31(1), 75–81. https://doi.org/10.1097/JCP.0b013e31820568c6
   PubMed Web of Science ®Google Scholar
• Roy, M. A., Lanctôt, G., Mérette, C., Cliche, D., Fournier, J. P., Boutin, P., Rodrigue, C., Charron, L., Turgeon, M., Hamel, M., Montgrain, N., Nicole, L., Pirès, A., Wallot, H., Ponton, A. M., Garneau, Y., Dion, C., Lavallée, J. C., Potvin, A., Szatmari, P., & Maziade, M. (1997). Clinical and methodological factors related to reliability of the best-estimate diagnostic procedure. The American Journal of Psychiatry, 154(12), 1726–1733. https://doi.org/10.1176/ajp.154.12.1726
   PubMed Web of Science ®Google Scholar
• Schreiner, A., Aadamsoo, K., Altamura, A. C., Franco, M., Gorwood, P., Neznanov, N. G., Schronen, J., Ucok, A., Zink, M., Janik, A., Cherubin, P., Lahaye, M., & Hargarter, L. (2015). Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophrenia Research, 169(1–3), 393–399. https://doi.org/10.1016/j.schres.2015.08.015
   PubMed Web of Science ®Google Scholar
• Secher, R. G., Hjorthøj, C. R., Austin, S. F., Thorup, A., Jeppesen, P., Mors, O., & Nordentoft, M. (2015). Ten-year follow-up of the OPUS specialized early intervention trial for patients with a first episode of psychosis. Schizophrenia Bulletin, 41(3), 617–626. https://doi.org/10.1093/schbul/sbu155
   PubMed Web of Science ®Google Scholar
• Stip, E., Abdel-Baki, A., Roy, M. A., Bloom, D., & Grignon, S. (2019). [Long-acting antipsychotics: The QAAPAPLE algorithm review]. Canadian Journal of Psychiatry, 64(10), 697–707. https://doi.org/10.1177/0706743719847193
   PubMed Web of Science ®Google Scholar
• Subotnik, K. L., Casaus, L. R., Ventura, J., Luo, J. S., Hellemann, G. S., Gretchen-Doorly, D., Marder, S., & Nuechterlein, K. H. (2015). Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. JAMA Psychiatry, 72(8), 822–829. https://doi.org/10.1001/jamapsychiatry.2015.0270
   PubMed Web of Science ®Google Scholar
• Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011). A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. The American Journal of Psychiatry, 168(6), 603–609. https://doi.org/10.1176/appi.ajp.2011.10081224
   PubMed Web of Science ®Google Scholar
• Tiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., & Taipale, H. (2017). Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry, 74(7), 686–693. https://doi.org/10.1001/jamapsychiatry.2017.1322
   PubMed Web of Science ®Google Scholar
• Tiihonen, J., Wahlbeck, K., Lonnqvist, J., Klaukka, T., Ioannidis, J. P., Volavka, J., & Haukka, J. (2006). Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ, 333(7561), 224. https://doi.org/10.1136/bmj.38881.382755.2F
   PubMed Web of Science ®Google Scholar
• Toll, A., Mané, A., Bergé, D., Gómez-Pérez, L., Samsó, B., Chavarria, V., & Pérez-Solà, V. (2015). Decreased incidence of readmission in first episode psychosis in treatment with long – acting injectable antipsychotics. European Psychiatry, 30, 231. https://doi.org/10.1016/S0924-9338(15)30189-9
   Web of Science ®Google Scholar
• Zhang, H., Turkoz, I., Zhuo, J., Mathews, M., Tan, W., & Feng, Y. (2017). Paliperidone palmitate improves and maintains functioning in Asia–Pacific patients with schizophrenia. Advances in Therapy, 34(11), 2503–2517. https://doi.org/10.1007/s12325-017-0638-0
   PubMed Web of Science ®Google Scholar